For a better experience, click the Compatibility Mode icon above to turn off Compatibility Mode, which is only for viewing older websites.

The disciplines of pharmacology and physiology touch on virtually every field of the biomedical sciences, presenting endless opportunities to discover disease mechanisms and develop new treatments. This translational approach is at the basis of our work, firmly rooted in the concept of promoting a seamless and continuous transition between the basic and the clinical sciences.

Our faculty pursue a variety of scientific interests in the areas of neurological disorders, cancer therapeutics, pain, cardiovascular and renal physiology, substance abuse, HIV neuropathology and comorbidities. We invite you to visit their laboratory pages and learn more about ongoing research projects and available openings. Feel free to inquire if you have any questions!

New Faculty Positions Available

The Department of Pharmacology and Physiology at Drexel University College of Medicine announces the opening of two tenure-track faculty positions, with an anticipated start date of July 1, 2017.
Read more [PDF]

Our training programs provide students with a wealth of advantages in considering career opportunities within academic and biopharmaceutical settings. We offer both traditional, research-intensive graduate programs in Pharmacology and Physiology (MS and PhD), as well as a recently developed program in Drug Discovery and Development.

News and Announcements

March 2017

Drs. Fatatis and Kim to Present at Coulter Forum

Congratulations to Alessandro Fatatis, MD, PhD, and his team (Kerberos Biopharmaceuticals)* and Felix Kim, PhD, and his team (Context Therapeutics)* whose projects were selected for presentation at the Coulter Investment Forum being held in Ann Arbor/Ypsilanti, Michigan, May 16-17, 2017.  The teams will present their work, which is supported in part by the Coulter-Drexel Translational Research Awards:

  • Fatatis/Kerberos project: “New Small Molecule Compounds for the Therapy of Metastatic Cancer
  • Kim/Context project: “Lead Optimization of Sigma1 Inhibitor for Castration-Resistant Prostate Cancer

*For more information about the Drexel-Coulter program or Kerberos/Context start-ups, please visit:

February 2017

Dr. Kim and Colleagues Publish in Cancer Research

Congratulations to Felix Kim, PhD, and his group, who recently published a new study in the journal Cancer Research. This work sheds light on a key mechanism of prostate cancer progression and was done in collaboration with Dr. Karen E. Knudsen, director of the Sidney Kimmel Cancer Center (SKCC) and chair of cancer biology at Thomas Jefferson University. The publication is entitled "Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer" (Thomas, JD, et al, Cancer Research [9.329] February 24, 2017).

See all news

See full seminar calendar

 Back to Top

Olimpia Meucci, MD, PhD, Professor & Chair, Department of Pharmacology & Physiology

Olimpia Meucci, MD, PhD
Professor & Chair

Upcoming Events